Allergen assay is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with enzymes or, less often, acid or heat to break peptide bonds. The starting material is typically sweet whey or acid whey from cheese making, first concentrated and dried into whey protein concentrate or isolate. Hydrolysis shortens long protein chains into smaller peptides, changing functional properties such as solubility, viscosity, and foam formation. The resulting powder contains peptides, residual intact protein, moisture, minerals, and variable amounts of lactose and fat depending on the starting material.
Enzymatic hydrolysis usually uses proteases from microbial, plant, or animal sources. The enzyme choice, pH, temperature, and reaction time determine which peptide bonds are cleaved and the final peptide profile. After hydrolysis, the enzyme is inactivated by heat, and the mixture is clarified, filtered, concentrated, and spray-dried. Manufacturers may use ultrafiltration to remove larger peptides or minerals. The degree of hydrolysis, often reported as a percentage, describes the proportion of peptide bonds broken. A higher degree generally means shorter peptides, but it does not by itself define taste, allergenicity, or biological activity.
Quality control for hydrolyzed whey protein focuses on composition, peptide size, and batch consistency. Protein content is commonly measured by Kjeldahl or combustion analysis, while moisture and ash are determined by gravimetric methods. Peptide molecular weight distribution is often assessed by size exclusion chromatography or mass spectrometry. The extent of hydrolysis can be estimated by titration, trinitrobenzenesulfonic acid assays, or formol titration. Because hydrolysis produces a complex mixture, no single test captures every relevant property, and laboratories often combine several methods.
Allergen testing is relevant because whey is a milk-derived ingredient. Immunoassays can detect residual milk proteins, but hydrolysis may alter or destroy antibody-binding sites, leading to false negatives or underestimation. Liquid chromatography with tandem mass spectrometry can identify specific peptide markers and is less dependent on intact protein epitopes. Regulatory labeling rules for milk allergens vary by country, and a product described as hydrolyzed is not automatically exempt from allergen declaration. For infants, specialized formulas require strict control of protein molecular weight and sterility, which adds testing beyond routine composition.
Physical properties such as particle size, bulk density, and reconstitution behavior affect handling and finished product quality. Water activity and moisture content influence shelf life; high moisture can promote caking, browning, and microbial growth. Color is monitored because Maillard reactions between peptides and reducing sugars can darken the powder during storage. Taste panels and instrumental methods may assess bitterness, which is a common challenge for hydrolysates. Specifications often include limits for heavy metals, microbiological counts, and residual fat, depending on the intended market.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to cream powder | Color can vary with starting whey and drying conditions |
| Protein content | Typically 70-90% dry basis | Depends on whether concentrate or isolate is used |
| Degree of hydrolysis | Often 5-30% for commercial hydrolysates | Ranges vary by intended application and process |
| Solubility | High in water at neutral pH | Smaller peptides generally dissolve more readily than intact protein |
| Common synonyms | Hydrolyzed whey protein; whey peptide | Terms are not always standardized across suppliers |
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with proteolytic enzymes. The starting material is whey, the liquid remaining after cheese or casein production, and its main proteins include beta-lactoglobulin, alpha-lactalbumin, and bovine serum albumin. Enzyme action breaks peptide bonds, producing shorter peptides and some free amino acids. The result is not a single uniform substance; composition depends on whey source, enzyme type, hydrolysis conditions, and downstream filtration. Hydrolysates are often described by average peptide length or degree of hydrolysis rather than by one fixed molecular weight.
Compared with whey protein concentrate or isolate, hydrolysate has a smaller average peptide size and a higher proportion of low-molecular-weight fractions. This change can affect solubility, viscosity, osmolality, taste, and foam formation. Some hydrolysates are bitter because hydrophobic peptides are exposed during cleavage. The term hydrolysate does not indicate a guaranteed peptide profile; two products with the same reported hydrolysis value can differ in peptide sequence and residual intact protein. Commercial specifications usually state protein content, moisture, ash, fat, and microbiology, while peptide distribution may be reported as a range.
Industrial production begins with whey protein concentrate or isolate dispersed in water. Selected proteases, such as trypsin, pepsin, or microbial enzymes, are added under controlled pH and temperature. Hydrolysis continues until a target hydrolysis level is reached, after which heat or pH adjustment inactivates the enzyme. Ultrafiltration, diafiltration, and ion exchange may remove larger peptides, salts, or residual lactose. The liquid is then concentrated and spray-dried into powder. Processing choices influence peptide size, bitterness, mineral content, and microbial quality.
Analytical control focuses on protein content, hydrolysis extent, molecular weight distribution, and residual intact protein. Kjeldahl or Dumas methods measure total nitrogen, while size-exclusion chromatography or mass spectrometry estimates peptide profiles. Sodium dodecyl sulfate polyacrylamide gel electrophoresis can show remaining intact proteins, though small peptides may not resolve. Enzyme-linked immunosorbent assays are used to assess residual allergenic proteins in some contexts. Because no single method captures all relevant features, manufacturers combine several assays and report values against internal specifications.
Whey protein hydrolysate is made by cleaving peptide bonds in whey proteins. The starting material is usually whey protein concentrate or isolate obtained during cheese or casein production. Proteolytic enzymes, acid, or heat can drive hydrolysis, although commercial processes favor controlled enzymatic treatment. The degree of hydrolysis describes the proportion of peptide bonds broken and separates partial from extensive hydrolysates. The resulting powder contains short peptides, free amino acids, residual intact protein, minerals, lactose, and fat in proportions that depend on the starting whey and downstream filtration.
Molecular weight distribution is a central compositional feature, and hydrolysis shifts the population toward lower-mass peptides, often below ten kilodaltons in extensively treated products. Enzyme choice, reaction time, temperature, pH, and enzyme-to-substrate ratio influence the peptide profile. Ultrafiltration or diafiltration may remove enzymes, salts, and smaller molecules. Because peptide size affects solubility, taste, foaming, and digestibility, manufacturers specify molecular weight ranges. However, two hydrolysates with similar average molecular weight can differ in peptide sequence and functional behavior.
Quality control for whey protein hydrolysate begins with specification of protein, moisture, ash, fat, lactose, and degree of hydrolysis, while molecular weight distribution is measured by size-exclusion chromatography or electrophoresis. Free amino acid content can be quantified by amino acid analysis. Microbial limits, heavy metals, and residual enzyme activity are also monitored. Because hydrolysis conditions influence batch consistency, manufacturers validate processes and test each lot against release criteria. Sampling plans and reference standards help compare results across laboratories.
Storage stability depends on moisture, temperature, oxygen, and packaging, and hydrolysates are hygroscopic and can cake when exposed to humid air. Maillard reactions between peptides and residual lactose can cause browning and flavor changes during warm storage, while lipid oxidation may develop if residual fat is present. Cool, dry conditions and sealed containers slow these reactions. Shelf-life studies typically monitor moisture, color, solubility, molecular weight profile, and microbial counts over time. Accelerated tests estimate stability, but real-time data remain the reference for shelf-life assignment.
== Contribution, awards and achievements == He was awarded the Fellowship of Rockefeller Foundation Fellow in USA during 1960–61; Commonwealth Medical Fellowship and then Wellcome Research Fellowship in England during the 1970s. In London at the National Institute for Medical Research, he worked on mechanism of action of Pyrogen and in the field of thermoregulation, with Wilhelm Feldberg (1900–1993), a German-British-Jewish pharmacologist and biologist. Wilhelm Feldberg assisted many research workers who came to England as a part of their Commonwealth Medical Fellowship and Wellcome Research Fellowship. Under these Fellowships, Saxena and Feldberg published many papers during the 1970s. In total, Saxena has approximately 145 published research papers. He wrote Hospital Formulary in 1969 and a book-cum-manual for practical pharmacy and experimental pharmacology laboratory. He had been founding member of many academic bodies such Indian Pharmacological Society, Association of Physiologists and Pharmacologists of India, Indian Medical Association, Indian Academy of Neurosciences and Indian Association for the Advancement of Medical Education in India. Indian National Science Academy (INSA) elected him Fellow (FNA) in 1987.
Recent advancements on the nanoscale such as devices that fabricate both spherical and non-spherical droplets that are ultrafast and homogeneous mixed are being produced for large scale production of powdered particles in industrial applications. Monodispersed nanoparticles are also of great interest in catalyst fabrication. Many heterogeneous catalytic systems efficiencies rely on high surface areas of transition metal particles. Microfluidic techniques have been used to fabricate gold nanoparticles through the interfacial interaction of droplets containing gold chloride, hexane, and a reducing agent with a surrounding aqueous phase. This process can also control both the size and shape of nanoparticles/nanosheets with precision and high throughput compared to other methods such as physical vapor deposition. The use of droplets containing various materials such as silica or transition metals such as gold flowed through an immiscible oil phase has been shown to be effective in controlling both size of nanoparticles as well as pore size, which allows for design of efficient absorptive gas capture devices and heterogeneous catalysts. Monodispersed nanoparticles of gold and silver have been synthesized using gold and silver chloride droplets dosed with a reducing agent to cleave metal-ligand bonds, leading to the agglomeration of monodispersed metal nanoparticles which can be easily filtered out of solution.
=== European Union === The European Union defines a VOC as "any organic compound as well as the fraction of creosote, having at 293.15 K a vapour pressure of 0.01 kPa or more, or having a corresponding volatility under the particular conditions of use;". The VOC Solvents Emissions Directive was the main policy instrument for the reduction of industrial emissions of volatile organic compounds (VOCs) in the European Union. It covers a wide range of solvent-using activities, e.g. printing, surface cleaning, vehicle coating, dry cleaning and manufacture of footwear and pharmaceutical products. The VOC Solvents Emissions Directive requires installations in which such activities are applied to comply either with the emission limit values set out in the Directive or with the requirements of the so-called reduction scheme. Article 13 of The Paints Directive, approved in 2004, amended the original VOC Solvents Emissions Directive and limits the use of organic solvents in decorative paints and varnishes and in vehicle finishing products. The Paints Directive sets out maximum VOC content limit values for paints and varnishes in certain applications. The Solvents Emissions Directive was replaced by the Industrial Emissions Directive from 2013.
Sources: en.wikipedia.org
In 1981, a commercial involving a train was made, the musical theme was "La Colegiala" composed by Rodolfo Aicardi. Due to the enormous popularity of Nescafé, during the Second World War, "all the production of the American plant was reserved only for the use of the military". In Ecuador, a Boeing 737-200 from the AeroGal company was painted red to promote the brand. In Chile, since 2009 the brand has sponsored and helped to restore a well-known Chilean theater that was in decline, making it the first Nescafé theater in the world and naming it the Nescafé Theater of the Arts. In previous years, the brand was sponsoring different stars of Canal 13, such as Esta Noche Fiesta and Tuesday 13, the 123 Nescafé competition and was for some time the sponsor of different campaigns of the Chilean Telethon, returning as sponsor to the campaign in 2011. In turn, its variant Nescafé Dolca was sponsor of Una Vez Más of Canal 13. In the Philippines, an advertising commercial was released in 2020 with their newest jingle and slogan, "Babangon tayo, susulong tayo" ("We will rise, we will advance"). English rock band Muse successfully sued Nescafé in 2003 when their song "Feeling Good" was used in a television ad without permission and donated the £500,000 compensation to Oxfam.
=== Impact of nucleation === Nucleation lays the foundation for the nanoparticle synthesis. Initial nuclei play a vital role on the size and shape of the nanoparticles that will ultimately form by acting as templating nuclei for the nanoparticle itself. Long-term stability is also determined by the initial nucleation procedures. Homogeneous nucleation occurs when nuclei form uniformly throughout the parent phase and is less common. Heterogeneous nucleation, however, forms on areas such as container surfaces, impurities, and other defects. Crystals can form simultaneously when nucleation occurs rapidly, resulting in a more uniform (monodisperse) product. In contrast, slow nucleation rates often lead to a diverse (polydisperse) population of crystals with varying sizes. This phenomenon is exemplified in the formation of CaCO3 crystals. Controlling nucleation allows for the control of size, dispersity, and phase of nanoparticles. The process of nucleation and growth within nanoparticles can be described by nucleation, Ostwald ripening or the two-step mechanism-autocatalysis model.
Sepharose is a tradename for a crosslinked, beaded-form of agarose, a polysaccharide polymer material extracted from seaweed. Its brand name is a portmanteau derived from Separation-Pharmacia-Agarose. A common application for the material is in chromatographic separations of biomolecules. Sepharose is a registered trademark of Cytiva (formerly: GE Healthcare and Pharmacia, Pharmacia LKB Biotechnology, Pharmacia Biotech, Amersham Pharmacia Biotech, and Amersham Biosciences). Various grades and chemistries of sepharose are available. Iodoacetyl functional groups can be added to selectively bind cysteine side chains and this method is often used to immobilize peptides. Sepharose/agarose, combined with some form of activation chemistry, is also used to immobilize enzymes, antibodies and other proteins and peptides through covalent attachment to the resin. Common activation chemistries include cyanogen bromide (CNBr) activation and reductive amination of aldehydes to attach proteins to the agarose resin through lysine side chains.
Sources: en.wikipedia.org
=== Familia Infini === The Japan only special model Familia Infini was introduced in February 1990 to celebrate Mazda's 70th anniversary. Based on the GT saloon, the 1.6 L DOHC B6-ZE engine was swapped to a bigger 1.8 L DOHC BP-ZE engine from the Protegé LX and international market 323 GT (it later became the standard engine for Familia GT in 1991), and teamed with a close ratio LSD 5-speed manual transmission. The Infini was upgraded with a viscous limited-slip differential, stiffer suspension package, and bonnet/headlight from the 323 hatchbacks (in 1991, these were adopted on all Familia saloon models). The Infini came only in dark green color with unique Infini aerodynamic grille, rear spoiler with third stop lamp, "lightweight" carpet, without sound deadener, and with Infini (∞) logos on horn button, front grille, wheel caps, and bootlid. There were also unique factory front clear indicators, a Momo Cobra II steering wheel, BBS 15-inch rims, faux suede interior with GT-X style seat trim, leather gearknob and shift boot, front and rear strut braces, 22-mm sway bars front and rear, rear tie bar, a quick-ratio steering and a 7,250 rpm redline tachometer, as well as 250 mm (9.8 in) four-wheel disc brakes. Around 1,000 Infinis were produced, and preceded Mazda's ɛ̃fini Japanese dealership network.
=== Future Outlooks of DNA Legos === DNA Legos have promising applications in drug encapsulation and intracellular delivery. DNA nanoparticles are created to have reactive groups with two pegs in a singular direction and two holes in another . This structure allows the bricks to connect and create various shapes. The shapes of the bricks can become complex to encapsulate various drug molecules. These shapes have been applied in an attempt to improve cancer immunotherapies. For example, DNA Legos have been formed into a star shape with sticky ends to encapsulate doxorubicin. When mixed in solution the sticky ends rapidly join together forming an icosahedron shaped brick with the anticancer drug inside of this structure. Another study investigated cellular uptake of spherical nucleic acid bricks (SNAs). Through SNA and dendritic cell interactions, tumor cells are efficiently killed as the spherical brick shape allows for tunable subcellular trafficking and peptide retention. Thus, creating various shaped DNA brick nanoparticles may improve efficacy of immunotherapies by encapsulating drug cargo improving cell uptake. Before DNA Legos can have clinical applicability as a nanoparticle, they must be stabilized to ensure proper drug release. Previously, RNA bricks have been locked in place by magnesium. Utilizing magnesium to set the shape of RNA bricks via kissing interactions allows for easy tunability of structures. This idea is easily translatable to DNA thus creating a mechanism in which DNA Legos can be stabilized for clinical use.
== Research == It has been studied as a method to stimulate the immune system as part of the treatment of cancer. It has also shown some efficacy in the treatment of nephrotic syndrome in children. After being pulled from the market in the US and Canada in 1999 and 2003, respectively, levamisole has been tested in combination with fluorouracil to treat colon cancer. Evidence from clinical trials support its addition to fluorouracil therapy to benefit patients with colon cancer. In some of the leukemic cell line studies, both levamisole and tetramisole showed similar effect.
Sources: en.wikipedia.org
It is whey protein that has been partially broken down into smaller peptides through hydrolysis. The powder still contains a mixture of peptides, residual protein, minerals, and other whey components. It is used as a food ingredient rather than a single pure compound.
Proteases cleave peptide bonds, reducing molecular size and altering solubility, viscosity, and taste. The extent of change depends on the enzyme and reaction conditions. Hydrolysis does not remove all intact protein or guarantee a specific peptide profile.
Degree of hydrolysis is the percentage of peptide bonds cleaved during the reaction. It is a processing measure, not a direct measure of peptide size distribution or function. Two products with the same degree can still differ in peptide sequence and sensory properties.
Size exclusion chromatography separates peptides by molecular size in solution, and mass spectrometry can provide more detailed mass information. Results are usually reported as a distribution rather than a single value. Method choice and calibration affect the reported range.